Physician profile
Jacquelyn E Powers
NPI 1578677605
$1,049.56
in general payments reported to CMS, 2019-2025
11 companies · $42.56 in 2025
The $42.56 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $150 · 2021: $202 · 2022: $28.44 · 2024: $178 · 2025: $42.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $221.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $410.20 | 2019-2025 | Precision 1 |
| New World Medical,INC. | $178.48 | 2024 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Abb Con-Cise Optical Group LLC | $102.90 | 2019 | |
| Glaukos Corporation | $100.61 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $80.36 | 2019-2021 | |
| Optos, INC. | $63.19 | 2019 | |
| Kala Pharmaceuticals, INC. | $31.78 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.03 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.65 | 2019 | |
| Lumenis, INC | $17.25 | 2021 | |
| Coopervision INC. | $17.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelyn Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.